Prof João Gonçalves speaks to ecancer at the 2019 Biosimilars Educational Advanced Masterclass for Pharmacists (P-BEAM) in Zurich about the importance of immunogenicity for all biological agents, including biosimilarity.

He emphasises that biosimilars need to be comparable to the originator product and the importance of monitoring therapy.

Prof Gonçalves also explains the factors that affect the immunogenicity of a drug and how it is assessed.

ecancer's filming has been kindly supported by Amgen through the ecancer Global Foundation. ecancer is editorially independent and there is no influence over content.

If you would like to learn more about biosimilar medicines, please visit our free e-learning modules here.